Liquid biopsy is a revolutionary diagnostic technique that enables the non-invasive detection and analysis of biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other molecules present in bodily fluids like blood, urine, or cerebrospinal fluid. Unlike traditional tissue biopsies, which involve invasive procedures to obtain tissue samples from tumors, liquid biopsy offers a minimally invasive approach for monitoring cancer progression, treatment response, and the emergence of resistance mutations. This technique holds immense promise in oncology by providing clinicians with real-time and comprehensive information about a patient’s cancer status, including genetic mutations, tumor heterogeneity, and the potential for metastasis.

Liquid biopsy also facilitates the identification of actionable genetic alterations, guiding the selection of targeted therapies and enabling personalized treatment strategies tailored to individual patients. Moreover, liquid biopsy holds potential beyond oncology, with applications in infectious disease monitoring, prenatal screening, and transplant rejection surveillance, underscoring its versatility and significance in modern medicine.

The demand for liquid biopsy is propelled by several key factors reshaping the landscape of cancer diagnosis and treatment. One primary demand driver is the increasing recognition of the limitations and challenges associated with traditional tissue biopsies, including invasiveness, sampling bias, and the inability to capture tumor heterogeneity. Liquid biopsy offers a non-invasive alternative that allows for repeated sampling and real-time monitoring of tumor dynamics, providing valuable insights into disease progression and treatment response.

Additionally, the growing emphasis on precision medicine and personalized oncology drives the demand for liquid biopsy tests, as they enable the identification of specific genetic mutations and molecular alterations guiding targeted therapy selection. The rise in cancer incidence globally further amplifies the need for more accessible and efficient diagnostic tools capable of detecting cancer at early stages when treatment is most effective. Moreover, advancements in technology, such as Next-Generation Sequencing (NGS) and digital PCR, enhance the sensitivity and specificity of liquid biopsy assays, expanding their utility in clinical practice and fuelling market demand.

In terms of revenue, the global liquid biopsy market was worth US$ 6.5 Bn in 2023, anticipated to witness CAGR of 12.2% during 2024 – 2034.

Global Liquid Biopsy Market Dynamics

Rising Cancer Incidence: The increasing prevalence of cancer globally serves as a primary driver for the liquid biopsy market, as these tests offer non-invasive methods for early detection, monitoring, and treatment response assessment. Increased patient awareness of liquid biopsy benefits, such as reduced invasiveness and potential for early disease detection, contributes to market growth by driving demand for these tests.

Technological Advancements: Ongoing advancements in sequencing technologies, such as Next-Generation Sequencing (NGS) and digital PCR, enhance the sensitivity and specificity of liquid biopsy assays, expanding their utility in clinical settings. Liquid biopsy applications are expanding beyond oncology to include infectious disease monitoring, prenatal screening, and transplant rejection monitoring, broadening the market potential.

Growing Adoption of Precision Medicine: The shift towards personalized treatment approaches drives demand for liquid biopsy tests, as they enable the identification of specific genetic mutations and molecular alterations guiding targeted therapy selection. Growing investments in research and development initiatives fuel innovation in liquid biopsy technologies, leading to the development of novel assays and biomarkers.

Cancer Application Segment has Garnered Major Market Share in the Global Liquid Biopsy Market During the Forecast Period (2024 – 2034).

Cancer applications of liquid biopsy represent a significant demand driver in the medical field, spurred by the need for non-invasive and real-time monitoring of cancer progression and treatment response. Liquid biopsies offer a minimally invasive alternative to traditional tissue biopsies, enabling the detection and analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers present in bodily fluids like blood or urine.

This approach is particularly valuable for patients with advanced or metastatic cancer, where obtaining tissue samples may be challenging or risky. Additionally, liquid biopsy facilitates the identification of actionable genetic mutations and allows for the early detection of treatment resistance, guiding more personalized and effective therapeutic interventions. The growing prevalence of cancer globally, coupled with advancements in technology and the increasing adoption of precision medicine approaches, fuels the demand for liquid biopsy-based cancer applications as essential tools in oncology research and clinical practice.

By Technology Multi-Gene Parallel Analysis using NGS Segment had the Highest Share in the Global Liquid Biopsy Market in 2023.

The integration of Multi-gene Parallel Analysis using Next-Generation Sequencing (NGS) technology into liquid biopsy methods emerges as a significant demand driver in the healthcare sector. This advanced approach enables the simultaneous analysis of multiple genes from circulating tumor DNA (ctDNA) or other biomarkers present in bodily fluids, revolutionizing cancer diagnostics and treatment monitoring. The demand for such precision medicine tools stems from the increasing recognition of the heterogeneity of cancer and the need for comprehensive molecular profiling to guide targeted therapies effectively.

In addition, the rise in cancer incidence rates globally, coupled with the growing emphasis on early detection and personalized treatment strategies, further propels the adoption of multi-gene parallel analysis using NGS in liquid biopsies. Moreover, the continuous evolution and refinement of NGS technologies, alongside decreasing costs and improved accessibility, contribute to the expanding demand for these innovative diagnostic approaches, reshaping the landscape of cancer care.

By Region, North America Dominated the Global Liquid Biopsy Market in 2023.

In North America, the adoption of liquid biopsy techniques serves as a significant demand driver in the healthcare landscape. Liquid biopsy, a minimally invasive diagnostic method that analyses biomarkers circulating in bodily fluids like blood, presents a promising alternative to traditional tissue biopsies for detecting and monitoring diseases such as cancer. The region’s aging population, coupled with the increasing prevalence of cancer and other chronic diseases, amplifies the demand for more accessible and timely diagnostic tools.

Liquid biopsy offers several advantages, including the ability to track disease progression, monitor treatment efficacy, and detect early-stage cancers, thereby facilitating more personalized and targeted therapies. Furthermore, the strong research and development infrastructure in North America, along with favorable regulatory policies promoting innovation in healthcare, fosters the adoption of liquid biopsy technologies, positioning it as a vital component in the fight against cancer and other diseases in the region.

Competitive Landscape: Global Liquid Biopsy Market:

• Biocept Inc.
• Bio-Rad Laboratories
• F. Hoffmann-La Roche Ltd.
• Guardant Health
• Illumina, Inc.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V
• Thermo Fisher Scientific Inc.
• Other Industry Participants

Global Liquid Biopsy Market Scope

Global Liquid Biopsy Market

By Product & Service

• Assay Kits
• Instruments
• Services

By Circulating Biomarker

• Circulating Tumor Cells
• Circulating Tumor DNA
• Cell-free DNA
• Extracellular Vesicles
• Other Circulating Biomarkers

By Clinical Application

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring

By Technology

• Multi-gene Parallel Analysis using NGS
• Single-gene Analysis using PCR

By Application

• Cancer Applications
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Other Cancers
• Non-cancer Applications
  • Non-Invasive Prenatal Testing
  • Organ Transplantation
  • Infectious Disease Testing

By Sample Type

• Blood Sample
• Other Sample Types

By End User

• Reference Laboratories
• Hospitals and Physician Laboratories
• Academic & Research Centers
• Other End Users

By Region

• North America (U.S., Canada, Mexico, Rest of North America)
• Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
• Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
• Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
• Latin America (Brazil, Argentina, Rest of Latin America)

Report Layout:

Table of Contents

.

.

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

.

**Exclusive for Multi-User and Enterprise User.

Global Liquid Biopsy Market

By Product & Service

• Assay Kits
• Instruments
• Services

By Circulating Biomarker

• Circulating Tumor Cells
• Circulating Tumor DNA
• Cell-free DNA
• Extracellular Vesicles
• Other Circulating Biomarkers

By Clinical Application

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring

By Technology

• Multi-gene Parallel Analysis using NGS
• Single-gene Analysis using PCR

By Application

• Cancer Applications
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Other Cancers
• Non-cancer Applications
  • Non-Invasive Prenatal Testing
  • Organ Transplantation
  • Infectious Disease Testing

By Sample Type

• Blood Sample
• Other Sample Types

By End User

• Reference Laboratories
• Hospitals and Physician Laboratories
• Academic & Research Centers
• Other End Users

By Region

• North America (U.S., Canada, Mexico, Rest of North America)
• Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
• Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
• Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
• Latin America (Brazil, Argentina, Rest of Latin America)

The Niche Research approach encompasses both primary and secondary research methods to provide comprehensive insights. While primary research is the cornerstone of our studies, we also incorporate secondary research sources such as company annual reports, premium industry databases, press releases, industry journals, and white papers.

Within our primary research, we actively engage with various industry stakeholders, conducting paid interviews and surveys. Our meticulous analysis extends to every market participant in major countries, allowing us to thoroughly examine their portfolios, calculate market shares, and segment revenues.

Our data collection primarily focuses on individual countries within our research scope, enabling us to estimate regional market sizes. Typically, we employ a bottom-up approach, meticulously tracking trends in different countries. We analyze growth drivers, constraints, technological innovations, and opportunities for each country, ultimately arriving at regional figures.Our process begins by examining the growth prospects of each country. Building upon these insights, we project growth and trends for the entire region. Finally, we utilize our proprietary model to refine estimations and forecasts.

Our data validation standards are integral to ensuring the reliability and accuracy of our research findings. Here’s a breakdown of our data validation processes and the stakeholders we engage with during our primary research:

• Supply Side Analysis: We initiate a supply side analysis by directly contacting market participants, through telephonic interviews and questionnaires containing both open-ended and close-ended questions. We gather information on their portfolios, segment revenues, developments, and growth strategies.
• Demand Side Analysis: To gain insights into adoption trends and consumer preferences, we reach out to target customers and users (non-vendors). This information forms a vital part of the qualitative analysis section of our reports, covering market dynamics, adoption trends, consumer behavior, spending patterns, and other related aspects.
• Consultant Insights: We tap into the expertise of our partner consultants from around the world to obtain their unique viewpoints and perspectives. Their insights contribute to a well-rounded understanding of the markets under investigation.
• In-House Validation: To ensure data accuracy and reliability, we conduct cross-validation of data points and information through our in-house team of consultants and utilize advanced data modeling tools for thorough verification.

The forecasts we provide are based on a comprehensive assessment of various factors, including:

• Market Trends and Past Performance (Last Five Years): We accurately analyze market trends and performance data from preceding five years to identify historical patterns and understand the market’s evolution.
• Historical Performance and Growth of Market Participants: We assess the historical performance and growth trajectories of key market participants. This analysis provides insights into the competitive landscape and individual company strategies.
• Market Determinants Impact Analysis (Next Eight Years): We conduct a rigorous analysis of the factors that are projected to influence the market over the next eight years. This includes assessing both internal and external determinants that can shape market dynamics.
• Drivers and Challenges for the Forecast Period:Identify the factors expected to drive market growth during the forecast period, as well as the challenges that the industry may face. This analysis aids in deriving an accurate growth rate projection.
• New Acquisitions, Collaborations, or Partnerships: We keep a close watch on any new acquisitions, collaborations, or partnerships within the industry. These developments can have a significant impact on market dynamics and competitiveness.
• Macro and Micro Factors Analysis:A thorough examination of both macro-level factors (e.g., economic trends, regulatory changes) and micro-level factors (e.g., technological advancements, consumer preferences) that may influence the market during the forecast period.
• End-User Sentiment Analysis: To understand the market from the end-user perspective, we conduct sentiment analysis. This involves assessing the sentiment, preferences, and feedback of the end-users, which can provide valuable insights into market trends.
• Perspective of Primary Participants: Insights gathered directly from primary research participants play a crucial role in shaping our forecasts. Their perspectives and experiences provide valuable qualitative data.
• Year-on-Year Growth Trend: We utilize a year-on-year growth trend based on historical market growth and expected future trends. This helps in formulating our growth projections, aligning them with the market’s historical performance.

Research process adopted by TNR involves multiple stages, including data collection, validation, quality checks, and presentation. It’s crucial that the data and information we provide add value to your existing market understanding and expertise. We have also established partnerships with business consulting, research, and survey organizations across regions and globally to collaborate on regional analysis and data validation, ensuring the highest level of accuracy and reliability in our reports.